Progress in brain research
-
Several studies have demonstrated that meditation naïve subjects can, in just a few weeks, become proficient enough in meditation to show cognitive improvements accompanied with functional and structural changes in the brain. Would long-term exposure to qualitatively different levels of meditative training bring about differences in cognitive processing? Would meditation prior to task performance help separate out these differences? Could the nature of the task influence the findings related to cognitive enhancements? To address these questions, we evaluated cognitive functions in three groups of experienced Vipassana practitioners (Novices: n=22, Mean±SD meditation experience=989±595h; Senior practitioners: 21, 10,510±5313; Teachers: 16, 14,648±9623) who differed in terms of duration and quality of meditative practice. Specifically, we employed "ANGEL" a gamified multilevel oddball paradigm, to assess P3 event-related potentials (ERPs) and associated EEG dynamics-power spectra, event related spectral perturbations (ERSP) and inter-trial coherence (ITC). ⋯ Specifically, we found reduced theta synchrony, enhanced alpha de-synchrony and lesser theta-alpha coherence in the more proficient meditators. Post hoc analyses revealed several differences between the novice and teacher groups but not as many between novice and seniors suggesting that the senior meditators formed an intermediate group. Our study demonstrates that both quantity and quality of meditation influence EEG dynamics during cognitive processing and that meditation prior to a task can provide additional state-trait effects involved in meeting the specific cognitive demands.
-
Depression and anxiety are psychiatric diagnoses commonly associated with low quality of life and low percentage of responsiveness by patients treated with currently available drugs. Thus, research into alternative compounds to treat these disorders is essential to guarantee a patient's remission. The last decade has witnessed a revamped interest for the application of psychedelic medicine for the treatment of mental disorders due to anecdotal reports and clinical studies which show that low doses of d-lysergic acid diethylamide (LSD) and psilocybin may have antidepressant effects. ⋯ LSD, belonging to the category of "classic halluginogens," interacts with the 5-HT system through 5HT1A, and 5HT2A receptors, with the DA system through D2 receptors, and indirectly also the glutamatergic neurotransmission thought the recruitment of N-methyl-d-aspartate (NMDA) receptors. Randomized clinical studies have confirmed its antidepressant and anxiolytic effects in humans. Thus, in this chapter, we will review the pharmacology of psychedelic drugs, report the most striking clinical evidence which substantiate the therapeutic potentials of these fascinating compounds in mood disorders, and look into the horizon of where psychedelic medicine is heading.
-
This chapter is an introduction to the volume "Psychedelic Neuroscience" of Elsevier's Progress in Brain Research addressing the neurobiological mechanisms of psychedelic drugs, the resulting changes in brain activity and integration of traditional viewpoints. As the field is relatively new, there are discrepancies in the literature related to classification, composition and effects of the various psychedelics. Currently, psychedelics are grouped according to their neuro-receptor affinities into classic and atypical psychedelics, each with individual treatment potentials and abilities to elicit potent acute experiences and long-lasting changes in neurobiology through concurrent activation of several neuromodulatory systems. ⋯ The term "psychedelic" means mind-revealing and psychedelics have exceptional anti-amnesic effects and are able to "make conscious" that which was previously unconscious through changes in brain "state," but also there is growing evidence which demonstrates the role of epigenetic mechanisms. This supports traditional therapeutic use of psychedelics to heal ancestral trauma. Details of these mechanisms are provided along with suggestions for further research.
-
Depending on its nature, duration, and intensity, stress can exert potent and bidirectional modulatory effects on pain, either reducing pain (stress-induced analgesia) or exacerbating it (stress-induced hyperalgesia). The descending pain pathway has been implicated in both stress-induced analgesia and stress-induced hyperalgesia. ⋯ Here we review the evidence for a key role of the endogenous opioid system in stress-induced modulation of pain in rodents and humans. Understanding the neurobiological mechanisms underlying opioidergic regulation of stress-pain interactions may help in identifying novel therapeutic strategies for the improved treatment of comorbid pain and stress-related disorders.